Clinical Trial

Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma

Study acronym: SPARTANA
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 22, 2023 (before its estimated June 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study evaluates the feasibility of the combination of radiotherapy, chemotherapies (docetaxel, cisplatin and 5-fluorouracil) and spartalizumab (anti-PD-1 therapy) in patients with metastatic squamous cell anal carcinoma
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-05-17; most recent amendment 2023-12-21.
Status change: Not Yet Recruiting → Recruiting 2022-03-10
Trial Details
NCT Number NCT04894370
Lead Sponsor Centre Hospitalier Universitaire de Besancon
Collaborators: National Cancer Institute, France, Novartis
Conditions Squamous Cell Anal Carcinoma, Metastatic Squamous Cell Carcinoma
Enrollment 34 participants
Start Date 2022-06-09
Primary Completion 2025-06-01 (estimated)
Study Completion 2026-11-01 (estimated)
Updated on ClinicalTrials.gov 2023-12-22